Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients

Experimental and Therapeutic Medicine

Volumn 6, Issue 4, 2013, Pages 977-982

  Fu, Chengcheng ^a   Wang, Juan ^a   Xin, Xue ^a   Liu, Hui ^a   Xue, Shengli ^a   Ma, Xiao ^a   Jin, Zhengming ^a   Sun, Aining ^a   Qiu, Huiying ^a   Wu, Depei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Autologous hematopoietic stem cell transplantation; Multiple myeloma; Prognosis

Indexed keywords

BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; LENALIDOMIDE; MELPHALAN; PLERIXAFOR; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT RESPONSE;

EID: 84883209891     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1261     Document Type: Article

References (23)

1. Kyle RA and Rajkumar SV: Multiple myeloma. New Engl J Med 351: 1860-1873, 2004.
2. Talamo G, Farooq U, Zangari M, et al: Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk 10: 464-468, 2010.
3. Myeloma Trialists' Collaborative group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16: 3832-3842, 1998.
4. Bladé J, Rosiñol L, Cibeira MT, Rovira M and Carreras E: Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 115: 3655-3663, 2010.
5. Anderson KC, Alsina M, Bensinger W, et al: Multiple myeloma. J Natl Compr Canc Netw 9: 1146-1183, 2011.
6. Brenner H, Gondos A and Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111: 2521-2526, 2008.
7. Lahuerta JJ, Mateos MV, Martínez-López J, et al: Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 26: 5775-5782, 2008.
8. Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021-1030, 2006.
9. Barlogie B, Pineda-Roman M, van Rhee F, et al: Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112: 3115-3121, 2008.
10. Harousseau JL and Moreau P: Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360: 2645-2654, 2009.
11. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W and Bayssas M: Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92: 1399-1406, 2007.
12. Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 28: 4621-4629, 2010.
13. Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106: 35-39, 2005.
14. Moreau P, Facon T, Attal M, et al: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study. J Clin Oncol 28 (Suppl 15): A8014, 2010.
15. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116: 679-686, 2010.
16. Roussel M, Moreau P, Huynh A, et al: Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 115: 32-37, 2010.
17. Harousseau JL, Attal M and Avet-Loiseau H: The role of complete response in multiple myeloma. Blood 114: 3139-3146, 2009.
18. Niesvizky R, Richardson PG, Rajkumar SV, et al: The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 143: 46-53, 2008.
19. Harousseau JL, Weber D and Dimopoulos M et al: Relapsed/refractory multiple myeloma treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response. Blood 110: 3598, 2007.
20. Pineda-Roman M, Zangari M, Haessler J, et al: Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 140: 625-634, 2008.
21. Spencer A, Prince HM, Roberts AW, et al: Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27: 1788-1793, 2009.
22. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108: 3289-3294, 2006.
23. Moreau P, Avet-Loiseau H, Harousseau JL and Attal M: Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 29: 1898-1906, 2011.